Search clinical trials for: Tucidinostat

Total 22 results

Wuhan Union Hospital, China

Not yet recruiting

Tucidinostat Plus Apatinib for Advanced Osteosarcoma

Osteosarcoma
Great Novel Therapeutics Biotech & Medicals Corporation

Recruiting

Chidamide in Patients With Relapsed or Refractory Peripheral T-cell Lymphoma (R/R PTCL)

Relapsed or Refractory Peripheral T-cell Lymphoma

Taiwan
The First Affiliated Hospital of Soochow University

Recruiting

Chidamide, Azacitidine Combined With GM Regimen for Relapsed and Refractory DLBCL Patients

Diffuse Large B-Cell Lymphoma

China
Great Novel Therapeutics Biotech & Medicals Corporation

Recruiting

Chidamide + Regorafenib in Hepatocellular Carcinoma (HCC)

Hepatocellular Carcinoma (HCC)

Taiwan
Sun Yat-sen University

Recruiting

Chidamide Combined With Zimberelimab in the Treatment of Metastatic Triple-negative Breast Cancer Patients

Triple Negative Breast Cancer

China
Hunan Cancer Hospital

Recruiting

Tucidinostat and Nab-paclitaxel in Advanced HR+/HER2- Breast Cancer

HR+/HER2- Breast Cancer

China
Ruijin Hospital

Recruiting

A Umbrella Study in R/R PTCL Guided by Molecular Subtypes

Peripheral T Cell Lymphoma

China
Chipscreen Biosciences, Ltd.

Recruiting

A Study of Tucidinostat Combined With Tislelizumab as First-line Treatment in Advanced NSCLC

Non Small Cell Lung Cancer

China
wang shusen

Recruiting

Tucidinostat Combined With Metronomic Capecitabine and Endocrine Therapy for Advanced HR-positive, HER2-negative Breast Cancer After CDK4/6 Inhibitor.

Breast Cancer

China
wang shusen

Recruiting

Tucidinostat and Metronomic Capecitabine for Metastatic Triple-negative Breast Cancer:a Multicenter,Open-label, Randomized Controlled, Phase II Clinical Trial

Triple Negative Breast Cancer

China
Yizhuo Zhang

Recruiting

Tucidinostat Plus Etoposide in the Treatment of Neuroblastoma in Childhood. (CSIIT-Q36)

Neuroblastoma in Children

China
Henan Cancer Hospital

Recruiting

Iribrine Plus Tucidinostat in the Treatment of HR+/HER2 Advanced Breast Cancer After CDK4/6 Inhibitor Failure

HR Positive HER2 Negative Advanced Breast Cancer

China
Taipei Medical University Shuang Ho Hospital

Recruiting

Chidamide + Celecoxib in Advanced Metastatic Colorectal Cancer (CCmCC)

Metastatic Colorectal Cancer

Taiwan
Beijing 302 Hospital

Recruiting

Outcome of Tucidinostat-Based Therapy in HR+ Metastatic Breast Cancer Patients Previously Treated With CDK4/6 Inhibitor

Breast Cancer

China
Ruihua Xu

Recruiting

Tucidinostat Plus PD-1 Inhibitor and Bevacizumab for Advanced Esophagus Cancer, AEG, Gastric Cancer

Esophageal Squamous Cell Cancer, Adenocarcinoma of Esophagogastric Junction, Gastric Adenocarcinoma

China
Peking Union Medical College Hospital

Recruiting

Tucidinostat, Azacitidine Combined With CHOP Versus CHOP in Patients With Untreated Peripheral T-cell Lymphoma

T-cell Lymphoma

China
Guangdong Women and Children Hospital

Not yet recruiting

Tucidinostat and Fulvestrant in Hormone-receptor Positive Advanced Breast Cancer

Breast Cancer
First Affiliated Hospital, Sun Yat-Sen University

Completed

Neoadjuvant Tucidinostat and Exemestane in Early Breast Cancer (NeoTEE)

Breast Cancer

China
Chipscreen Biosciences, Ltd.

Active, not recruiting

Phase III Study of Tucidinostat in Combination With R-CHOP in Patients With Newly Diagnosed Double-Expressor DLBCL (DEB)

Diffuse Large B-cell Lymphoma

China
HUYABIO International, LLC.

Active, not recruiting

A Study of HBI-8000 (Tucidinostat) With Pembrolizumab in Non-Small Cell Lung Cancer (HBI-8000)

Non Small Cell Lung Cancer

United States
oubai

Unknown

Maintenance Therapy of Chidamide in Patients With HBV Positive Diffuse Large B-cell Lymphoma

Diffuse Large B-cell Lymphoma

China
Gynecologic Oncology Group
National Cancer Institute (NCI)

Completed

Rilotumumab in Treating Patients With Persistent or Recurrent Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer

Recurrent Fallopian Tube Carcinoma | Recurrent Ovarian Carcinoma | Recurrent Primary Peritoneal Carcinoma

United States

3

Subscribe